PRPF6

Across TCGA pan-cancer cohorts, PRPF6 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of PRPF6’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where PRPF6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRPF6 is over-expressed in tumor, although a few such as UCEC and KICH show the opposite, repressed pattern.

STAD, COAD, and LIHC are the cancer types where PRPF6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRPF6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	Male	II,III,IV	+1.206	<.001	10	view →
COAD	Female	All	+1.124	<.001	10	view →
LIHC	Female	II,III,IV	+1.323	<.001	9	view →
HNSC	Male	All	+0.563	<.001	9	view →
KIRC	Female	All	+0.412	<.001	9	view →
UCEC	All	All	−0.516	.003	6	view →
CHOL	All	II,III,IV	+2.140	<.001	5	view →
READ	All	All	+0.618	.007	4	view →
LUSC	Male	II,III,IV	+0.528	.001	4	view →
BRCA	All	III,IV	+0.441	.020	4	view →
KIRP	All	II,III,IV	+0.396	.030	3	view →
ESCA	All	All	+0.621	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

PRPF6–STAD

Open the STAD breakdown →